Literature DB >> 7192079

Cisplatin-induced hypocalcemia and hypomagnesemia.

N W Lyman, C Hemalatha, R L Viscuso, M G Jacobs.   

Abstract

Cisplatin (cis-diamminedichloroplatinum), a chemotherapeutic agent active against solid tumors, is a known cause of acute renal failure and renal tubular dysfunction. We saw a case of renal magnesium wasting and hypomagnesemia in a 58-year-old woman with genital pelvic malignancy. Her initial manifestation was that of chronic symptomatic hypocalcemia of four months' duration. The relatively reduced parathyroid hormone level in this patient and the possible sites of cisplatin-induced renal tubular dysfunction resulting in hypermagnesuria were evaluated. This case emphasizes the importance of serially observing cisplatin-treated patients for the possible development of hypomagnesemic hypocalcemia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192079

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Lack of effect of oral magnesium on high blood pressure: a double blind study.

Authors:  F P Cappuccio; N D Markandu; G W Beynon; A C Shore; B Sampson; G A MacGregor
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-27

4.  Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: impact of tumour site, patient age and magnesium suppletion.

Authors:  J H Blom; K H Kurth; T A Splinter
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

5.  Cis-platinum treatment for malignancy-associated humoral hypercalcemia in an athymic mouse model.

Authors:  L J Kukla; E C Abramson; W P McGuire; D H Shevrin; T Lad; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

6.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

Review 7.  A clinical approach to common electrolyte problems: 4. Hypomagnesemia.

Authors:  C Berkelhammer; R A Bear
Journal:  Can Med Assoc J       Date:  1985-02-15       Impact factor: 8.262

Review 8.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

9.  Synergistic protective effect of N-acetylcysteine and taurine against cisplatin-induced nephrotoxicity in rats.

Authors:  Wessam M Abdel-Wahab; Farouzia I Moussa; Najwa A Saad
Journal:  Drug Des Devel Ther       Date:  2017-03-20       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.